Biotech · Mainz, Germany
Bring your ideas to life.
maintect develops rapid lateral flow tests for the early detection of disease and new antibody-based therapies, with a research focus on age-related macular degeneration (AMD).
About maintect
Diagnostics and therapy, from one lab.
What we do
Based on our expertise, we offer contract research for the development of rapid lateral flow tests for point-of-care diagnostics, as well as the development of new immunological therapy options for various diseases.
Who we are
maintect GmbH is a biotech company based in Mainz, Germany, dedicated to the development of immunochromatographic rapid test devices (lateral flow assays) for the early detection of disease and antibody-based treatments. Our immediate research and development goals include the point-of-care diagnosis of eye diseases including AMD, the development of minimally invasive sampling systems, and taking our AMD antibody treatment project to preclinical trials.
Our work is based on more than 10 years of research at the University of Mainz.
Why AMD matters
The leading cause of blindness in developed countries.
196 M
people were estimated to be living with AMD in 2020.
288 M
people are expected to be affected by 2040.
$343 bn
estimated global cost of visual impairment due to AMD.
Prevalence estimates: Wong et al.
Research focus · AMD
Towards a personalized AMD therapy.
AMD is a degenerative disease of the retina leading to a loss of visual function. It is one of the principal causes of visual impairment worldwide. Today’s gold-standard anti-VEGF therapy is expensive, and many patients do not respond to it.
We are bringing forward a new therapeutic approach, particularly for anti-VEGF non-responders, but also as a general new option for wet and dry AMD. In vitro and in vivo tests with our molecule of choice have generated very promising results and target a completely new therapeutic pathway.
Contract development
What we offer.
Besides our own research projects, maintect provides a specialized service platform for the development of your lateral flow assays (LFA) based on different body fluids, as well as contract work for immune therapy based on our expertise in antibody drug development.
01
Extensive experience in LFA
Antibody and antigen detection, multiplex formats and competitive assays, tailored to every requirement of your lateral flow assay.
02
Saliva-based lateral flow assay
A quick, non-invasive sampling system that neutralizes the inhibition exerted by saliva on the test line signal.
03
Autoantibody detection via lateral flow
Extensive knowledge in detecting autoimmune reactive antibodies via lateral flow assays or microarrays, for rapid point-of-care results.
04
Antibody drug development
Contract work to establish your own antibody treatment strategy, from whole antibodies to cost-effective paratope (CDR) sequences.
05
Software solutions
Our mobile app reads different lateral flow formats with a smartphone camera and uploads results to a central database.
Network
Our partners
Work with us
Let’s develop your rapid test together.
Lateral flow assay, autoantibody detection or antibody therapy: tell us about your project and we will get back to you.